Journal for ImmunoTherapy of Cancer · 2020 · 35 citations · 13 references
MedicineOncologyPathologyImmunotherapyMetastasisNeuro-oncologyBrain MetastasesBrain MetastasisBrain TumorsCancer ImmunotherapyImmuno-oncology BiomarkersNeuro-oncologic PathologyClinicopathological CorrelationImmunohistochemical BiomarkersImmunohistochemical DetectionImmunohistochemical StainingKaplan-meier Survival EstimatesProgrammed Cell Death Protein 1 (Pd-1) PathwayProgrammed Death-ligand 1 BiomarkerProgrammed Death-ligand 1 Upregulation
BACKGROUND: Brain metastases (Bmets) are frequent; however, limited data exist on the efficacy of immunotherapy in these lesions. The aims of the study were to analyze the immunohistochemical expressions of programmed death ligand 1 (PD-L1) and CD8 in Bmets and to compare them with their expressions in paired primary tumors, as well as correlate the results with clinicopathological features. METHODS: test, Cramer's V test, factorial analyses of variance, simple regression analysis, and Kaplan-Meier analysis with log-rank product limit estimation. RESULTS: PD-L1 expression was found in 23.6% of Bmets and in 29.0% of primary tumors with concordant expression between them in 75.5% of cases. Bmets PD-L1 expression was associated with primary tumor PD-L1 expression and the primary tumor type. Significant CD8 peritumoral expression was found in 68.6% of Bmets and in 87.7% of primary tumors. CD8 expression was concordant between primary and metastatic tumors in 73.3% of cases. Bmets CD8 expression was associated with primary tumor CD8 expression and primary tumor type. PD-L1 expression was associated with CD8 expression in both primary and metastatic tumors. The concordance between primary and metastatic tumor PD-L1 expression was independent of all factors studied. The concordance between primary and metastatic CD8 expressions was marginally associated to the time of Bmets development. No prognostic role for PD-L1 and CD8 expression in Bmets was found. CONCLUSION: PD-L1 and CD8 Bmets expressions are associated with the primary tumor type and its PD-L1 and CD8 expressions. No factor predicts the discordance for PD-L1 expression, while time to Bmets development is associated with CD8 expression discordance.
13
Epidemiology of Brain Metastases
Lakshmi Nayak, Eudocia Q. Lee, Patrick Y. Wen · Current Oncology Reports · 2011 · 1.4K citations
Sarah B. Goldberg, Scott Gettinger, Amit Mahajan et al. · The Lancet Oncology · 2016 · 996 citations · Full text
Medicine, Oncology, Pharmacology +16
Christian U. Blank, John B.A.G. Haanen, Antoni Ribas et al. · Science · 2016 · 731 citations
Medicine, Immunology, Oncology +14
Aaron S. Mansfield, MC Aubry, Justin C. Moser et al. · Annals of Oncology · 2016 · 336 citations · Full text